Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2021

01-12-2021 | Macroalbuminuria | Research

Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Authors: Wanwan Luo, Lingmin Zhang, Lingling Sheng, Zhencheng Zhang, Zaixing Yang

Published in: Diabetology & Metabolic Syndrome | Issue 1/2021

Login to get access

Abstract

Background

Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.

Methods

Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case–control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese. Finally, twenty-five studies were included in this meta-analysis.

Results

Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD = 1.62, 95% CI 1.08 to 2.25, P = 0.000; GDM: SMD = 2.85, 95% CI 1.01 to 4.70, P = 0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD = 1.58, 95% CI 0.59 to 2.56, P = 0.002; microalbuminuria: SMD = 2.57, 95% CI 0.92 to 4.22, P = 0.002; macroalbuminuria: SMD = 2.69, 95% CI 1.40 to 3.98, P = 0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD = 1.49, 95% CI 0.28 to 2.71, P = 0.016; macroalbuminuria vs microalbuminuria: SMD = 0.93, 95% CI 0.34 to 1.52, P = 0.002).

Conclusions

Our current meta-analysis demonstrates that serum level of YKL-40 is increased in DM and positively associated with the severe degree of albuminuria. Therefore, we suggest that YKL-40 could be considered to be detected, along with other inflammatory markers, if DM, especially DN, is suspected.
Literature
1.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):S67-74.CrossRef
2.
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–86.CrossRef
3.
Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metabol Res Rev. 2017;33:e2841.CrossRef
4.
Papadopoulou-Marketou N, Paschou SA, Marketos N, Adamidi S, Adamidis S, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes. Minerva Med. 2018;109:218–28.PubMed
5.
Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr DiabRep. 2013;13:435–44.CrossRef
6.
Halim M, Halim A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes Metabol Syndrome. 2019;13:1165–72.CrossRef
7.
Kumar P, Raman T, Swain MM, Mishra R, Pal A. Hyperglycemia-induced oxidative-nitrosative stress induces inflammation and neurodegeneration via augmented tuberous sclerosis complex-2 (TSC-2) activation in neuronal cells. Mol Neurobiol. 2017;54:238–54.PubMedCrossRef
8.
Chang SC, Yang WV. Hyperglycemia, tumorigenesis, and chronic inflammation. Critic Rev oncol hematol. 2016;108:146–53.CrossRef
9.
Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110:351–60.PubMed
10.
Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278:44058–67.PubMedCrossRef
11.
Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verheijden GF, et al. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum. 2000;43:1233–43.PubMedCrossRef
12.
Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflammat Res. 2006;55:221–7.CrossRef
13.
Han JY, Ma XY, Yu LJ, Shao Y, Wang QY. Correlation between serum YKL-40 levels and albuminuria in type 2 diabetes. Genet Mol Res. 2015;14:18596–603.PubMedCrossRef
14.
Han JY, Shao Y, Wang QY. The correlation of serum YKL-40 and albuminuria in type 2 diabetes. Chinese J Endocrinol Metabol. 2014;30:225–7.
15.
Li J, Niu G, Wang H, Wang K, Huang B, Li M. Serum YKL-40 levels in gestational diabetes mellitus. Gynecol Endocrinol. 2016;32:412–5.PubMedCrossRef
16.
Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflammat Res. 2006;55:53–9.CrossRef
17.
Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol. 2010;9:86.PubMedPubMedCentralCrossRef
18.
Schaller G, Brix JM, Placher-Sorko G, Hollerl F, Schernthaner GH, Schernthaner G. YKL-40 concentrations are not elevated in gestational diabetes. Eur J Clin Invest. 2010;40:339–43.PubMedCrossRef
19.
Sakamoto F, Katakami N, Kaneto H, Yasuda T, Takahara M, Miyashita K, et al. Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus. Endocr J. 2013;60:73–9.PubMedCrossRef
20.
Rinnov AR, Rathcke CN, Bonde L, Vilsboll T, Knop FK. Plasma YKL-40 during pregnancy and gestational diabetes mellitus. J Reprod Immunol. 2015;112:68–72.PubMedCrossRef
21.
Abd El Dayem SM, Battah AA, El Shehaby A, Abd Allah N. Assessment of human cartilage glycoprotein 39 (YKL-40), preptin, and nitric oxide in adolescent patients with type 1 diabetes and its relation to cardiorenal affection. J Pediat Endocrinol Metabol. 2015;28:309–14.
22.
Shiasi K, Talebian F, Khamechi SP, Nikoueinejad H, Sehat M, Azarbad Z, et al. Evaluation of YKL-40 serum level in patients with type 1 diabetes and its correlation with their metabolic and renal conditions. Nephro-Urol Month. 2017; 9.
23.
Rekha Kumari D, Farid Babu M, Balu MK. Human cartilage glycoprotein 39 (YKL-40): a View in type 2 diabetes mellitus. Int J Pharm Sci Res. 2015;6(11):4852–6.
24.
Song W, Zhang K, Dong LP, Lu W, Li CG, Luan J. Association between YKL-40 and type 2 diabetic microangiopathy. Chinese J Clin. 2015;9:3214–8.
25.
Ye KJ, Hao Q, Dai J, Ye XJ. Association between YKL-40 and gestational diabetes mellitus. China medical herald. 2016;13:75–8.
26.
Chen QF, Yi ZG, Guo WA. Association between YKL-40 and type 2 diabetes as well as lower extremity atherosclerosis. Guide China Med. 2014;12:78–9.
27.
Li P, Gao JD, Zhang HL, Ma SH, Du CG. Expression of YKL-40 and Chemerin in chronic complications of type 2 diabetes mellitus. Modern Med Health. 2011;27:2300–2.
28.
Lin LJ, Fan PY, Yao YL, Luo W, Jiang YP, Song K, et al. The relationship between serum YKL-40 and type 2 diabetic retinopathy and diabetic nephropathy. Chinese High Altit Med Biol. 2019;40(118–21):129.
29.
Xun SL, Hu JJ, Chen J, Zhang LL, Lu HM, Kong X. Expression and significance of YKL-40 in maternal blood and umbilical cord blood serum and placenta in patients with gestational diabetes mellitus. China Foreign Med Treat. 2017;10:52–5.
30.
Yu YY, Shi X, Pan JQ, Shi WW, Tan LY, Yu XJ. Study on the correlation between serum A-FABP and YKL-40 levels and insulin resistance in newly diagnosed T2DM patients. J Liaoning Med Univ. 2018;39:17–21.
31.
Ren LY, Wang YZ, Wei CY, Liu Y, Zheng LM. Correlation between levels of lipoprotein-associated phospholipase A2 and chitinase 3-like protein 1 with diabetes retinopathy in type 2 diabetes mellitus. China Health Standard Managem. 2019;20:27–30.
32.
Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care. 2009;32:323–8.PubMedPubMedCentralCrossRef
33.
Rondbjerg AK, Omerovic E, Vestergaard H. YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovascu Diabetol. 2011;10:54.CrossRef
34.
Lee JH, Kim SS, Kim IJ, Song SH, Kim YK, In Kim J, et al. Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. J Diabetes Complicat. 2012;26:308–12.CrossRef
35.
Umapathy D, Dornadula S, Krishnamoorthy E, Mariappanadar V, Viswanathan V, Ramkumar KM. YKL-40: A biomarker for early nephropathy in type 2 diabetic patients and its association with inflammatory cytokines. Immunobiology. 2018;223:718–27.PubMedCrossRef
36.
Zhu HJ, Yang MM, Cheng L, Zhu X, Cheng XB. The changes and clinical significance of serum YKL-40 level in type 2 diabetic patients with chronic kidney disease. Chinese J Diabetes. 2015;23:720–2.
37.
Wang H, Cui K, Xu K, Fang XX. Relationship between serum YKL-40 and atherosclerosis in patients with type 2 diabetic nephropathy. Chinese J Integrat Tradit Western Nephrol. 2015;16:57–8.
38.
Yu ZX, Wang YZ. YKL-40 and MPV in the clinical value of early diabetic nephropathy. Chinese J Clin. 2017;11:1110–3.
39.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.PubMedPubMedCentralCrossRef
40.
41.
Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889–94.PubMedCrossRef
42.
43.
44.
Treszl A, Szereday L, Doria A, King GL, Orban T. Elevated C-reactive protein levels do not correspond to autoimmunity in type 1 diabetes. Diabetes Care. 2004;27:2769–70.PubMedCrossRef
45.
Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia. 2002;45:151.PubMedCrossRef
46.
Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:455–61.PubMedCrossRef
47.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.PubMedCrossRef
48.
King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79:1527–34.PubMedCrossRef
49.
Østergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol. 2002;9:598–604.PubMedPubMedCentral
50.
Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2000;59:544–8.PubMedPubMedCentralCrossRef
51.
52.
Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, et al. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol. 1993;264:E60–7.PubMed
53.
Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol. 1999;180:903–16.PubMedCrossRef
54.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32.PubMedCrossRef
55.
Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ. 1988;296:156–60.PubMedCrossRefPubMedCentral
56.
Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44:1957–72.PubMedCrossRef
57.
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327–40.PubMedCrossRef
58.
Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143–59.CrossRef
59.
Brix JM, Hollerl F, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 in type 2 diabetic patients with different levels of albuminuria. Eur J Clin Invest. 2011;41:589–96.PubMedCrossRef
60.
Yasuda T, Kaneto H, Katakami N, Kuroda A, Matsuoka TA, Yamasaki Y, et al. YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract. 2011;91:e50–2.PubMedCrossRef
Metadata
Title
Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis
Authors
Wanwan Luo
Lingmin Zhang
Lingling Sheng
Zhencheng Zhang
Zaixing Yang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2021
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-021-00624-9

Other articles of this Issue 1/2021

Diabetology & Metabolic Syndrome 1/2021 Go to the issue

Research

Oxidative phenotype induced by aerobic physical training prevents the obesity-linked insulin resistance without changes in gastrocnemius muscle ACE2-Angiotensin(1-7)-Mas axis

Research

Circ-FBXW12 aggravates the development of diabetic nephropathy by binding to miR-31-5p to induce LIN28B

Review

The effect of vitamin C supplementation on lipid profile of type 2 diabetic patients: a systematic review and meta-analysis of clinical trials

Review

Diet-induced obesity in animal models: points to consider and influence on metabolic markers

Correction

Correction to: Improvements in cholesterol efux capacity of HDL and adiponectin contribute to mitigation in cardiovascular disease risk after bariatric surgery in a cohort with morbid obesity

Research

Hesperidin alleviates insulin resistance by improving HG-induced oxidative stress and mitochondrial dysfunction by restoring miR-149

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits